title: Idarucizumab for dabigatran reversal - Does one dose fit all?
authors.affiliation: Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: Amihai
authors.initials: A
authors.lastname: Rottenstreich
authors.affiliation: Coagulation Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: Nivin
authors.initials: N
authors.lastname: Jahshan
authors.affiliation: Coagulation Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: Limor
authors.initials: L
authors.lastname: Avraham
authors.affiliation: Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Electronic address: ykalish@gmail.com.
authors.forename: Yosef
authors.initials: Y
authors.lastname: Kalish
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000069604:Dabigatran / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C000594745:idarucizumab; D000069604:Dabigatran